

# Arnold S Freedman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6332819/arnold-s-freedman-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

3,466  
citations

29  
h-index

58  
g-index

75  
ext. papers

3,877  
ext. citations

4.4  
avg, IF

5.17  
L-index

#	Paper	IF	Citations
72	Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. <i>New England Journal of Medicine</i> , <b>1991</b> , 325, 1525-33	59.2	566
71	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , <b>1999</b> , 94, 3325-3333	2.2	295
70	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , <b>2016</b> , 128, 195-203	2.2	222
69	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1598-1605	2.2	208
68	Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2554-9	2.2	191
67	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3128-35	2.2	159
66	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , <b>2016</b> , 29, 574-586	24.3	154
65	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. <i>Blood</i> , <b>2005</b> , 105, 489-95	2.2	144
64	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>2002</b> , 117, 828-34	4.5	116
63	Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3036-43	2.2	113
62	Unbalanced Expression of Bcl-2 Family Proteins in Follicular Lymphoma: Contribution of CD40 Signaling in Promoting Survival. <i>Blood</i> , <b>1998</b> , 91, 244-251	2.2	106
61	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , <b>2019</b> , 134, 22-29	2.2	78
60	Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 282-91	4.5	69
59	Follicular lymphoma: 2018 update on diagnosis and management. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 296-305	7.1	64
58	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>1999</b> , 5, 262-8	4.7	63
57	Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1797-803	2.2	59
56	Expression and regulation of CD5 on in vitro activated human B cells. <i>European Journal of Immunology</i> , <b>1989</b> , 19, 849-55	6.1	59

55	Follicular lymphoma: 2020 update on diagnosis and management. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 316-327	7.1	59
54	Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 258-65	4.5	54
53	Follicular lymphoma: 2014 update on diagnosis and management. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 429-36	7.1	51
52	CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 492-5	4.5	46
51	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 89-95	4.5	44
50	Functional effects of TNF and lymphotoxin alpha1beta2 on FDC-like cells. <i>Cellular Immunology</i> , <b>2000</b> , 203, 134-43	4.4	44
49	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. <i>Haematologica</i> , <b>2014</b> , 99, 1421-32	6.6	42
48	Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 86, 121-7	4	36
47	Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 28, 65-72	1.9	36
46	Follicular lymphoma: 2012 update on diagnosis and management. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 988-95	7.1	34
45	Follicular lymphoma: 2011 update on diagnosis and management. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 768-75	7.1	32
44	Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. <i>British Journal of Haematology</i> , <b>2003</b> , 122, 745-59	4.5	30
43	Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 247-255	11.6	26
42	Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>1995</b> , 17, 87-93	1.9	25
41	MCP-1 modulates chemotaxis by follicular lymphoma cells. <i>British Journal of Haematology</i> , <b>2001</b> , 115, 554-62	4.5	24
40	Biology and management of histologic transformation of indolent lymphoma. <i>Hematology American Society of Hematology Education Program</i> , <b>2005</b> , 2005, 314-20	3.1	23
39	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , <b>2020</b> , 4, 858-867	7.8	21
38	Follicular lymphoma: 2015 update on diagnosis and management. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 1171-8	7.1	18

37	B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. <i>Lancet Oncology, The</i> , <b>2004</b> , 5, 711-7	21.7	17
36	Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 377-86	5.8	15
35	Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 315-20	1.9	15
34	High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 28, 219-30	1.9	15
33	Adhesion of follicular lymphoma cells to lymphoid germinal centers--a potential mechanism of tumor cell homing following autologous transplantation. <i>Leukemia and Lymphoma</i> , <b>1994</b> , 13, 47-52	1.9	11
32	Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2002</b> , 8, 429-34	4.7	10
31	Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E95-E98	7.1	10
30	Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 902-9	1.9	9
29	Expression of vascular cell adhesion molecule-1 by follicular dendritic cells. <i>Leukemia and Lymphoma</i> , <b>1995</b> , 18, 259-64	1.9	8
28	The relationship of chronic lymphocytic leukemia to normal activated B cells. <i>Leukemia and Lymphoma</i> , <b>1990</b> , 1, 293-300	1.9	6
27	Autologous bone marrow transplantation therapy for multiple myeloma. <i>European Journal of Haematology</i> , <b>1989</b> , 51, 157-63	3.8	4
26	Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 1663-6	1.9	4
25	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , <b>2018</b> , 132, 145-145	2.2	4
24	B-cell monoclonal antibodies and their use in clinical oncology. <i>Cancer Investigation</i> , <b>1991</b> , 9, 69-84	2.1	3
23	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 706-706	2.2	3
22	Phase III Trial of Active Immunotherapy (FavId , Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin Lymphoma (fNHL).. <i>Blood</i> , <b>2006</b> , 108, 2756-2756	2.2	3
21	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 1635-1635	2.2	3
20	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 522-522	2.2	3

19	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 1650-1650	2.2	2
18	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , <b>2007</b> , 110, 1358-1358	2.2	2
17	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 3156-3156	2.2	2
16	Non-transplant-related treatment options in follicular lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2006</b> , 12, 53-8	4.7	1
15	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , <b>2011</b> , 118, 2865-2865	2.2	1
14	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.. <i>Blood</i> , <b>2012</b> , 120, 2875-2875	2.2	1
13	Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. <i>Ecological Management and Restoration</i> , <b>2017</b> , 30, 1-8	3	1
12	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	0
11	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	0
10	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e139-e140	2.2	
9	Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Long Term Follow up of Two Sequential Trials with Standard Dose and High Dose CHOP Induction.. <i>Blood</i> , <b>2004</b> , 104, 5243-5243	2.2	
8	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. <i>Blood</i> , <b>2006</b> , 108, 3041-3041	2.2	
7	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 2331-2331	2.2	
6	Non-Myeloablative Allogeneic Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , <b>2007</b> , 110, 3041-3041 <sup>2.2</sup>		
5	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , <b>2015</b> , 126, 4001-4001	2.2	
4	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2011</b> , 118, 465-465	2.2	
3	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , <b>2012</b> , 120, 1980-1980 <sup>2.2</sup>		
2	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 4567-4567	2.2	

- 1 Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. *Current Hematologic Malignancy Reports*, **2016**, 11, 218-23

4-4